Maximising the Taste and Health Value of Plant Food Products (MAXVEG)

March 10, 2015 updated by: Per Bendix Jeppesen, Aarhus University Hospital

Maximising the Taste and Health Value of Plant Food Products - Impact on Vegetable Consumption, Consumer Preferences and Human Health Factors.

To investigate if a high dietary intake of bitter and strong tasting vegetables have positive health effects (insulin sensitivity, glucose tolerance, central obesity, fasting and postprandial lipid profile, blood pressure, vitamin D status and inflammatory markers, biomarkers of oxidative stress) on subjects with T2D. Also to look at a high dietary intake of mild and sweet modern vegetables or a normal western diet.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The metabolic syndrome (MS), type 2 diabetes (T2D) and obesity are the world's most prevalent lifestyle diseases. This unfortunate development is mainly caused by lifestyle choices leading to obesity due to physical inactivity and excessive calorie intake.

Vegetables are an important part of the human diet and a major source of biologically active substances which determine the nutritional quality of food, color, taste, smell, antioxidative, anticarcinogenic, antihypertensive, anti-inflammatory, antihyperglycemia, immunostimulating and cholesterol-lowering properties.

Diet, as one aspect of lifestyle, is thought to be one of the modifiable variable risk factors for the development of MS and T2D, but more information is needed as to which components of the diet could be protective for the development and progression of MS and T2D with all its complications.

The study will be carried out as a 3-month randomized controlled parallel intervention study involving 60 subjects with T2D. During the fall year 2011 30 (10 in each group) subjects will participate and the remaining 30 subjects (10 in each group) in the fall 2012. The subjects will be randomized into 3 different diets:

  1. A) "A healthy Nordic diet" with high content of bitter strong tasting vegetables and cabbages.
  2. B) "A healthy Nordic diet" with high content of sweet and mild tasting vegetables and cabbages.
  3. C) A diet habitually consumed in the Nordic countries (normal control diet). The subjects in groups A and B will each have to consume 500 g root vegetables and cabbages daily which will be handed out once a week. The participants will visit the study clinic at screening, and then once weekly during the intervention period (12 weeks). Beside the screening examination there will be 3 major visits (0, 6 and 12 weeks) where the participants will collect urine samples, complete a 3-day weighed food diary (to control diet intake) and undergo clinical examination incl. measuring of blood pressure, body composition and collection of fasting blood samples i.e. glucose, insulin, glucagon, HbA1c, GLP-1, lipids (triglycerides, HDL-, LDL- and total cholesterol), cytokines, adipokines, parathyroid hormone and vitamin D. During first (week 0) and third (week 12) major visit a 120 minutes oral glucose tolerance test is included collecting blood to analyze for glucose, insulin and triglycerides.

The study will contribute to the understanding on the impact of a diet with a high level of root vegetables and cabbages with either high or low levels of phytochemicals. Furthermore, the results can be used to develop new recommendations targeted T2D and MS subjects, and thereby contribute to a healthier lifestyle and to prevent any further development and progression of these lifestyle diseases. The overall perspective of the MAXVEG project is to enhance the consumption and production of bitter and strong tasting health promoting root vegetables and cabbages with high phytochemical content and high consumer preferences targeted specific consumer groups

Study Type

Interventional

Enrollment (Actual)

92

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Nordjylland
      • Hjørring, Nordjylland, Denmark, 9800
        • Hospital Vendsyssel, Center for Clinical Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Type 2 diabetes in diet treatment or on oral anti-diabetic drug or the metabolic syndrome.

Exclusion Criteria:

  • Other severe diseases or in treatment with insulin, GLP-1 analogs, glitazones.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Diet intervention - Ancient vegatables
A healthy Nordic diet with high content of bitter strong tasting vegetables and cabbages.
The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
Other Names:
  • Vegetables
  • Ancient
  • Cabbages
  • Type 2 diabetes
No Intervention: Control Nordic diet
A diet habitually consumed in the Nordic countries
Experimental: Diet intervention - Modern Vegetables
A healthy Nordic diet with high content of sweet and mild tasting vegetables and cabbages.
The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
Other Names:
  • Vegetables
  • Ancient
  • Cabbages
  • Type 2 diabetes

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Insulin sensitivity
Time Frame: 2 years
Measured as the AUC from an Oral Glucose Tolerance Test
2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Urine and blood samples
Time Frame: 2 years

The fasting blood samples will be analyzed for: glucose, insulin, glucagon, HbA1c, lipids (triglycerides, HDL-, LDL- and total cholesterol), cytokines (, adipokines biomarkers of oxidative stress parathyroid hormone, vitamin D and GLP-1.

Urine samples for metabolomics (isoprostanes and water-soluble metabolites).

2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Per B Jeppesen, Prof. PhD, University of Aarhus

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2011

Primary Completion (Actual)

December 1, 2014

Study Completion (Actual)

January 1, 2015

Study Registration Dates

First Submitted

July 18, 2011

First Submitted That Met QC Criteria

July 19, 2011

First Posted (Estimate)

July 20, 2011

Study Record Updates

Last Update Posted (Estimate)

March 11, 2015

Last Update Submitted That Met QC Criteria

March 10, 2015

Last Verified

March 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 2 Diabetes

Clinical Trials on Diet intervention

Subscribe